The Cooper Companies, Inc. (COO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 7% revenue increase and 8% EPS growth. Despite a slight decrease in gross margin, operating margins remain stable. Positive projections for revenue and margin improvements, alongside strategic growth in contact lens and fertility segments, contribute to a positive outlook. The absence of discussed risks and stable capital expenditures further support this sentiment. However, the lack of specific shareholder return plans slightly tempers the overall positivity.
Key Financial Performance
Revenue $858 million, up 7% year-over-year, driven by strong performance in the CooperVision and CooperSurgical segments.
CooperVision Revenue $561 million, up 6% year-over-year, attributed to growth in daily silicone hydrogel lenses.
CooperSurgical Revenue $297 million, up 9% year-over-year, due to increased fertility product sales.
Gross Margin 67%, a decrease of 1% year-over-year, impacted by higher manufacturing costs.
Operating Margin 24%, consistent year-over-year, supported by cost control measures.
Earnings Per Share (EPS) $3.25, up 8% year-over-year, reflecting improved operational efficiency.
Free Cash Flow $150 million, up 15% year-over-year, driven by better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The transcript does not explicitly mention any risks or challenges related to market conditions.
Competitive Pressures: The transcript does not explicitly mention any risks or challenges related to competitive pressures.
Regulatory Hurdles: The transcript does not explicitly mention any risks or challenges related to regulatory hurdles.
Supply Chain Disruptions: The transcript does not explicitly mention any risks or challenges related to supply chain disruptions.
Economic Uncertainties: The transcript does not explicitly mention any risks or challenges related to economic uncertainties.
Strategic Execution Risks: The transcript does not explicitly mention any risks or challenges related to strategic execution risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects revenue growth in the mid-single digits for the fiscal year 2026, driven by strong performance in the contact lens segment and anticipated recovery in the fertility business.
Margin Projections: Operating margins are projected to improve by approximately 100 basis points, supported by cost optimization initiatives and favorable product mix.
Capital Expenditures: Capital expenditures are expected to remain stable, with investments focused on expanding manufacturing capabilities and enhancing digital infrastructure.
Market Trends: The company anticipates a gradual recovery in the global contact lens market, with growth opportunities in emerging markets and increased demand for daily disposable lenses.
Business Segment Performance: The fertility segment is expected to rebound with double-digit growth, supported by new product launches and strategic partnerships.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Bednar Piper
Blair LLC
BofA Securities
Brian Andrews
CFO Treasurer
Co Redburn
Co Research
Cooper Companies
Director Brian
Division Jason
Division Joanne
Division Jonathan
Division Larry
Division Lichtman
Division Marcus
Division Miksic
Division Navann
Division PM
Division Petrone
Division Roman
Division Travis
Division Young
EST name
Inc Research
Inc Vice
Incorporated Research
Instructions pleasure
Issie Kirby
Jefferies LLC
LLC Research
President Investor
Research Division
Vice President
COO Transcript
The Cooper Companies, Inc. (COO) Q2 2026 Earnings Call Transcript
Neutral6-5
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Unknown3-6
The earnings call revealed a 15% revenue increase and improved gross margins, but the company still reported a net loss. The lack of strategic initiatives and forward-looking guidance, coupled with a 5% rise in operating expenses, tempers the positive financial metrics. The acknowledgment of risks without specific mitigation strategies adds uncertainty. Overall, the mixed financial performance and absence of strategic discussion suggest a neutral sentiment.
The Cooper Companies, Inc. (COO) Q1 2026 Earnings Call Transcript
Positive3-6
The earnings call highlights strong financial performance with a 7% revenue increase and 8% EPS growth. Despite a slight decrease in gross margin, operating margins remain stable. Positive projections for revenue and margin improvements, alongside strategic growth in contact lens and fertility segments, contribute to a positive outlook. The absence of discussed risks and stable capital expenditures further support this sentiment. However, the lack of specific shareholder return plans slightly tempers the overall positivity.
The Cooper Companies, Inc. (COO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
COO Slides
COO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
